Skip to main content
XFOR logo

XFOR · X4 Pharmaceuticals, Inc

Track XFOR — free
$4.22 -0.07 (-1.63%) At close · Aug 14
Market Cap
$418.40M
Shares
99.15M

Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.

Revenue
$6.5M +150%
FY2025 Revenue FY2018–FY2025
Net Income
-$79.2M -111.5%
FY2025 Net Income FY2016–FY2025
Gross Margin
11.43% -57.9pp
FY2025 Gross Margin FY2024–FY2025
Operating Margin
-1336.66% +63.4pp
FY2025 Operating Margin FY2020–FY2025
Diluted EPS
-$1.87 +66.5%
FY2025 Diluted EPS FY2020–FY2025
Operating Cash Flow
-$85.62M +34.6%
FY2025 Operating Cash Flow FY2016–FY2025

Chart any reported metric, KPI or segment over time — the full statement history lives here

Line Item TTM FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018 FY2017 FY2016
$8.8M $6.5M $2.6M $0 $0 $0 $3M $0 $0
$2.93M $5.76M $797K $0 $0
$5.87M $743K $1.8M $0 $0
11.43% 69.35%
$66.39M $72.72M $81.64M $72.02M $61.06M $50.65M $41.93M $30.16M $20.35M $17.07M $17.83M
$34.44M $43.52M $61.52M $35.51M $27.02M $24.7M $20.94M $17.64M $8.74M $5.18M $6.52M
$500K $0 $0
$1.28M $796K $419K $513K $499K $351K $103K $103K $71K $285K
$7.01M $861K $2M
$115.51M $107.52M $87.57M $85.11M $62.87M $51.7M $29.09M $22.25M $24.35M
$38.96M $107.52M $87.57M
-$87.91M -$86.88M -$36.4M -$107.52M -$87.57M -$85.11M -$59.87M -$51.7M -$29.09M -$22.25M -$24.35M
-1336.66% -1400.04% -1995.8%
-$85.61M -$35.61M -$107.1M -$87.06M -$84.61M -$59.52M -$51.6M -$28.98M -$22.18M -$24.06M
$8.74M $8.88M $8.77M $5.78M $3.99M $3.64M $2.69M $2.15M $720K $490K $2.52M
$6.97M $4.58M $5.77M $4.58M $219K $10K $273K $1.2M $236K $64K
-$2.26M $7.73M -$739K $6.43M -$6.27M -$3.57M -$2.11M -$1.1M -$4.2M $253K $1.37M
-$90.17M -$79.16M -$37.14M -$101.09M -$93.84M -$88.68M -$61.98M -$52.81M -$33.29M -$21.99M -$22.98M
-$28K $41K $310K $78K $28K $17K $148K $0 $0
-$90.14M -$79.2M -$37.45M -$101.17M -$93.87M -$88.7M -$62.13M -$52.81M -$33.29M -$21.99M -$22.98M
-1218.45% -1440.38% -2071.03%
-$37.45M -$101.17M -$96.41M -$102.64M -$62.13M -$53.4M -$36.31M -$24.99M -$23M
-$37.45M -$101.17M -$93.87M -$88.7M -$62.13M -$52.93M -$33.29M -$21.99M -$22.86M
USD/shares -$1.87 -$5.59 -$17.07 -$45.60 -$119.70 -$92.70
USD/shares -$1.87 -$5.59 -$17.07 -$45.60 -$119.70 -$92.70
shares 42.29M 6.7M 5.93M 2.12M 858.29K 669.23K 384.33K 15.3K 15.27K 17.12K
shares 42.29M 6.7M 5.93M 2.12M 858.29K 669.23K 384.33K 15.3K 15.27K 17.12K
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.

Capital Returned to Shareholders

Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2019–FY2023: $2M in buybacks.

Price & Valuation

Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.

Valuation

EV/Revenue
33.90×
Peer median 4.40×
EV/EBIT
Peer median 9.72×
P/E (TTM)
Peer median 12.38×

Peer medians compare against the 326 similar-size Biotechnology companies (of 545 listed).

Valuation over time computed as of each quarter's filing date

Revenue Breakdown

Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.

Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.

By Segment (USD)

Component FY2025 FY2024 FY2023
Reportable Segment $35,113,000 $2,557,000 $0

By Geography (USD)

Component FY2024
Non Us $0

By Product & Service (USD)

Component FY2025 FY2024 FY2023
License and Other Revenue $28,590,000 $0 $0
Product $6,523,000 $2,557,000 $0
Key facts CIK 1501697 CUSIP 98420X202 13F (30d) 91 filings 88 filers Visit website Investor relations